| 000 | 01762 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516014759.0 | ||
| 264 | 0 | _c20111102 | |
| 008 | 201111s 0 0 eng d | ||
| 022 | _a1462-0332 | ||
| 024 | 7 |
_a10.1093/rheumatology/keq398 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKirchhoff, Timm | |
| 245 | 0 | 0 |
_aCost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings. _h[electronic resource] |
| 260 |
_bRheumatology (Oxford, England) _cApr 2011 |
||
| 300 |
_a756-61 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xeconomics |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCost Savings _xstatistics & numerical data |
| 650 | 0 | 4 | _aCost of Illness |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aEfficiency |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGermany _xepidemiology |
| 650 | 0 | 4 |
_aHealth Care Costs _xstatistics & numerical data |
| 650 | 0 | 4 |
_aHospitalization _xeconomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aRuof, Jörg | |
| 700 | 1 | _aMittendorf, Thomas | |
| 700 | 1 | _aRihl, Markus | |
| 700 | 1 | _aBernateck, Michael | |
| 700 | 1 | _aMau, Wilfried | |
| 700 | 1 | _aZeidler, Henning | |
| 700 | 1 | _aSchmidt, Reinhold E | |
| 700 | 1 | _aMerkesdal, Sonja | |
| 773 | 0 |
_tRheumatology (Oxford, England) _gvol. 50 _gno. 4 _gp. 756-61 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/keq398 _zAvailable from publisher's website |
| 999 |
_c20439464 _d20439464 |
||